New Delhi: Drugmaker Mylan NV said on Monday it secured approval to launch its generic version of Gilead Sciences Inc's Covid-19 treatment drug remdesivir in India this month at ₹4,800 per 100 mg vial, as infections surge in the world's third worst-hit country by the virus.
The Drug Controller General of India (DCGI) approved Mylan's remdesivir version, to be launched under brand name Desrem, for restricted emergency use in Covid-19 patients, the company said in a statement
Mylan secured regulatory approval for remdesivir lyophilized powder for injection of 100 mg/vial for restricted emergency use.
Mylan's version comes after two Indian drugmakers, Cipla Ltd and privately-held Hetero Labs Ltd, launched their generic versions of the drug.
Cipla will price its version, Cipremi, at less than ₹5,000, while Hetero has priced its version, Covifor, at ₹5,400.
Gilead has priced remdesivir at $2,340 per patient for wealthier nations. It has agreed to send nearly all of its supply of the drug to the United States over the next three months, stirring concerns about availability elsewhere.
Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial. On Friday, it got conditional approval from the European Commission for use in severe COVID-19 patients.
Mylan NV said Mylan will manufacture remdesivir in India at its injectables' facilities. The drug has been approved in India for the treatment of suspected or laboratory confirmed severe incidences of COVID-19 in adults and children, the company said in a statement.
Gilead has signed licensing agreements with India's Dr.Reddy's Laboratories Ltd, Jubilant Life Sciences Ltd, Syngene International Ltd and Zydus Cadila, listed as Cadila Healthcare Ltd, to make and sell remdesivir.
The Union Health Ministry on Friday has revised the dosage of the antiviral drug--remdesivir, being administered to hospitalized Covid-19 patients from the earlier six-days to five-day treatment course.
According to the Health Ministry, remdesivir drug is only for restricted emergency use on patients with moderate disease (those on oxygen support). The drug cannot be administered to a pregnant or lactating mother and children below the age of 12 years. Also, the drug is not recommended to a patient with severe renal impairment and a high level of liver enzymes.
The Central Health Ministry has issued a fresh clinical management protocol for COVID-19 patients on Friday. In the latest protocol, the ministry has informed the dosage of remdesivir should be-- 200 mg IV on day 1 followed by 100 mg IV daily for 4 days (5 days in total). However, in the previous clinical protocol issued on June 13, the Health Ministry stated that the patient has to be administered with 200 mg IV on day 1 followed by 100 mg IV daily for 5 days, that was, 6 days in total.
Jun 22, 2020 1 1935
Mar 15, 2021 0 18506
Mar 7, 2020 0 4087
Sep 12, 2020 3 14011
Aug 25, 2020 0 716
Apr 24, 2020 0 1383
Aug 26, 2019 0 6
Untouched by the outside world, Pulga has kept its local charm alive owing to its...
Aug 31, 2021 0 2774
The deadlines were extended by CBDT after taxpayers and other stakeholders raised...
Jul 6, 2021 0 118
Nov 22, 2019 0 1958
Two of the petrol offerings in the car include a 1.2-litre Kappa dual VTVT engine...
Aug 21, 2019 0 1056
Actress Parineeti Chopra gave a sneak peek into her intense look from the upcoming...
Aug 27, 2021 0 11
The new Redmi earbuds are likely to be called the Redmi Buds 3.
Aug 27, 2021 0 275
Setu has already created a beta version for the application programming interface.
Oct 9, 2020 0 1198
Chief minister Trivendra Singh Rawat directed Kumbh mela administration to assess...
Aug 3, 2021 0 68
According to experts, the intranasal vaccine can secure an immune response at the...
Jul 20, 2021 0 115
Sep 14, 2021 0 105
Sep 14, 2021 0 1
Sep 1, 2021 0 12512
Aug 31, 2021 0 2774
Aug 9, 2021 2 513
Aug 21, 2021 0 167
Aug 14, 2021 0 166
Aug 27, 2021 0 150
Aug 14, 2021 0 142